BioStock: Immunicum announces MERECA trial update

Immunicum’s phase II MERECA study testing ilixadencel in kidney cancer patients is entering the final stretch. Yesterday, the company announced an update on the study that seems to indicate that their candidate is providing a survival benefit to patients. BioStock reached out to Immunicum’s COO Sijme Zeilemaker to learn more.

Read the full interview with Sijme Zeilemaker at biostock.se:

https://www.biostock.se/en/immunicum-announces-mereca-trial-update/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se